The Gerard & Anton Awards ceremony highlights 10 promising start-ups in the Brainport Eindhoven region each year. Gilbert has been selected a one of the 2023 winners.
Click here for the article and interview.
Dutch MedTech Company Gilbert Raises €7 Million Series A to Redefine Treatment for Lung Patients.
Eindhoven, The Netherlands, June 7 2023 – Gilbert, today announced the completion of its €7 million Seed – and Series A investment round. The investment rounds are led by Dutch deeptech investor DeeptechXL and joined by existing shareholders NanoCorp and Delft Enterprises.
Click here for the full press release.
Engineering the inhaler of the future
What is the most important success factor to bring a medical technology from lab bench to hospital?
At the High Tech Campus Eindhoven Technology event, Maurits Huigen and Peter van den Bekerom discussed – on stage – how Gilbert and Philips Engineering Solutions partnered to develop the inhaler of the future.
Gilbert names Scott Fleming Chief Commercial Officer. Click here for the full press release.
Gilbert Announces George Hersbach to serve as Executive Chairman and Transition Role of CEO to Current COO Maurits Huigen. Click here for the full press release.
Interview with our COO Maurits Huigen after the nomination of Gilbert as one of the promising respiratory device solution providers by Medical Tech Outlook Magazine.
The startup company Gilbert R&D B.V., a subsidiary of Gilbert B.V., announces today that it has received funding for the development of a new generation soft mist inhalers for the precise administration of expensive medicines for people with lung disease. Gilbert has received financing from Brabant Startup Fonds B.V. (“BSF”).
English: Click here for the full text press release.
Dutch: Click here for the full text press release.
Belgium UCLouvain Louvain Drug Research Institute (LDRI) and Netherlands MedTech Start-up Gilbert join efforts for improved therapy for Cystic Fibrosis Patients.
LDRI receives funding for the development of a long-acting PEGylated rhDNase for CF-treatment with reduced therapeutic burden.
Click here for the full text press release.
MedTech Magazine, December 2018
When it comes to pulmonary drug administration and therapy adherence, it is noted that many of the commercially available inhalers such as Dry Powder Inhalers (DPIs) and Metered Dose Inhalers (MDIs) are relatively limited in their effectiveness. In this article, Maurits Huigen explains why and how Gilbert solves the limiting effects of current inhalers with a new finding using an electrospraying technique.
Read the full article published on Med Tech Outlook.